Recombinant Human VHL Protein，His & MBP

VHL (Von Hippel-Lindau) disease is a hereditary cancer syndrome characterized by the development of various tumors, particularly in the kidneys and central nervous system, due to mutations in the VHL gene. This gene encodes a protein that plays a crucial role in the regulation of hypoxia-inducible factors (HIFs), which are essential for cellular responses to low oxygen levels. Under normoxic conditions, the VHL protein facilitates the ubiquitination and subsequent degradation of HIFs, thereby preventing the activation of genes that promote angiogenesis and cell proliferation. However, mutations in the VHL gene lead to the stabilization of HIFs, resulting in uncontrolled cell growth and increased tumor risk. Research into the recombinant VHL protein has gained momentum as scientists seek to understand its structural and functional properties. This protein holds potential not only as a biomarker for VHL disease but also as a therapeutic target for strategies aimed at modulating HIF activity in various cancers. Studying VHL protein interactions and its role in the ubiquitin-proteasome pathway is vital for uncovering the underlying mechanisms of VHL-associated malignancies and developing novel intervention strategies. Advances in recombinant protein technology enable the production of functional VHL protein, allowing for in-depth biochemical analyses and the exploration of VHL’s interactions with other cellular components. Overall, the investigation of recombinant VHL protein is integral to elucidating the pathophysiology of VHL disease, enhancing our understanding of tumor biology, and paving the way for innovative therapeutic approaches.